-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
ESLOF:OTC- (USD)
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 222.9Change
+2.93 (+1.33)%Market Cap
USD 102.50BVolume
200.00Verdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 222.9Change
+2.93 (+1.33)%Market Cap
USD 102.50BVolume
200.00Verdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ESLOY | Essilor International SA |
N/A |
USD 100.19B |
HOCPF | HOYA Corporation |
N/A |
USD 40.96B |
HOCPY | Hoya Corp |
N/A |
USD 40.66B |
RSMDF | Resmed Inc DRC |
N/A |
USD 28.14B |
CLPBF | Coloplast A/S |
N/A |
USD 27.05B |
CLPBY | Coloplast A |
N/A |
USD 26.98B |
TRUMF | Terumo Corporation |
N/A |
USD 26.03B |
TRUMY | Terumo Corp ADR |
N/A |
USD 24.60B |
SAUHF | Straumann Holding AG |
N/A |
USD 21.26B |
SAUHY | Straumann Holding AG ADR |
N/A |
USD 19.73B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
C068:F | 2.63 % | 0.00 % |
N/A |
N/A | |
C068:XETRA | 2.63 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 11.90% | 83% | B | 69% | C- | ||
Dividend Return | 2.14% | 89% | A- | 45% | F | ||
Total Return | 14.03% | 78% | C+ | 70% | C- | ||
Trailing 12 Months | |||||||
Capital Gain | 17.19% | 87% | B+ | 74% | C | ||
Dividend Return | 2.24% | 62% | D | 30% | F | ||
Total Return | 19.42% | 84% | B | 73% | C | ||
Trailing 5 Years | |||||||
Capital Gain | 104.50% | 98% | N/A | 88% | B+ | ||
Dividend Return | 12.03% | 59% | D- | 42% | F | ||
Total Return | 116.53% | 96% | N/A | 88% | B+ | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 11.86% | 59% | D- | 58% | F | ||
Dividend Return | 13.28% | 56% | F | 56% | F | ||
Total Return | 1.42% | 53% | F | 29% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 21.93% | 90% | A- | 83% | B | ||
Risk Adjusted Return | 60.54% | 96% | N/A | 91% | A- | ||
Market Capitalization | 102.50B | 100% | F | 99% | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.